Aethlon Medical Reports Q2 2025 Financial Results

Aethlon ( (AEMD) ) has released its Q2 earnings. Here is a breakdown of the information Aethlon presented to its investors.

Aethlon Medical, Inc., a clinical-stage medical device company based in San Diego, focuses on developing the Hemopurifier to address unmet needs in oncology and infectious diseases by selectively removing pathogenic targets from biological fluids.

In its fiscal second quarter of 2025, Aethlon Medical reported significant progress in clinical trials and research collaborations, alongside a notable reduction in operating expenses. The company remains in compliance with Nasdaq listing requirements and continues to advance its oncology trial in Australia and Long COVID research in collaboration with UCSF.

Key financial highlights include a 48% reduction in operating expenses, bringing them down to $1.5 million from $2.9 million in the previous year, attributed to decreased payroll, general administrative costs, and professional fees. The company’s cash balance stood at approximately $5.8 million as of September 30, 2025. Aethlon’s ongoing clinical trials aim to evaluate the safety and efficacy of the Hemopurifier in cancer patients who have not responded to PD-1 therapy, with promising initial results observed in the reduction of extracellular vesicles and microRNAs.

The company is also exploring the Hemopurifier’s compatibility with a simplified blood treatment system, which could enhance its application in oncology units. Aethlon’s management emphasizes its commitment to maintaining operational discipline while pursuing its long-term goals in therapeutic device development.

Looking ahead, Aethlon Medical remains focused on executing its clinical and research strategies, with continued emphasis on cost management and strategic collaborations to support its mission of developing therapeutic solutions for cancer and life-threatening infectious diseases.